CARA - Cara Therapeutics concludes enrollment in mid-stage Korsuva dermatitis study

Cara Therapeutics (CARA) has completed enrollment of its KARE Phase 2 dose-ranging trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of moderate-to-severe pruritus (itchy skin) in atopic dermatitis patients. Topline data from this trial is expected in early 2021The 400-subject trial's primary efficacy endpoint is change from baseline in the weekly mean of the daily 24-hour Itch NRS score at week 12 of the treatment period.Earlier in July, the independent Data Monitoring Committee recommended to increase the size of enrollment in this Phase 2 trial, from 320 to 400.

For further details see:

Cara Therapeutics concludes enrollment in mid-stage Korsuva dermatitis study